Related Experiment Video
Updated: Jun 2, 2026
High Efficiency Differentiation of Human Pluripotent Stem Cells to Cardiomyocytes and Characterization by Flow Cytometry
Published on: September 23, 2014
A universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that
Paul W Burridge1, Susan Thompson, Michal A Millrod
1Johns Hopkins Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America. paul.burridge@jhmi.edu
Insights
Researchers developed an efficient system to produce functional cardiomyocytes from human induced pluripotent stem cells (hiPSC). This breakthrough offers improved methods for drug testing, disease modeling, and cardiac regeneration therapies.
Area of Science:
- Stem Cell Biology
- Cardiovascular Research
- Regenerative Medicine
Background:
- Human induced pluripotent stem cells (hiPSC) offer potential for patient-specific applications like drug testing and cardiac regeneration.
- Current hiPSC differentiation protocols are often inefficient and inconsistent.
- A novel system addresses these limitations for reliable cardiac cell production.
Purpose of the Study:
- To develop a highly efficient and universal system for cardiac differentiation of human pluripotent stem cells (hPSC), including hiPSC.
- To overcome the variability and inefficiency associated with existing differentiation methods.
- To establish a cost-effective method for generating functional cardiomyocytes.
Main Methods:
- Systematic optimization of over 45 experimental variables.
- Forced aggregation of embryoid bodies (hEB) in chemically defined media.
- Staged exposure to physiological oxygen (5%) and optimized growth factor concentrations (BMP4, FGF2).
Main Results:
- Achieved 94.7±2.4% efficiency in cardiac differentiation within nine days across multiple hESC and hiPSC lines.
- Generated contracting hEB composed of 64-89% cardiac troponin I-positive cells.
- Demonstrated functional properties of cardiomyocytes, including ultrastructural characteristics and drug responsiveness.
Conclusions:
- The developed system provides an efficient, cost-effective, and universal method for hiPSC-derived cardiomyocyte production.
- Enables potentially unlimited supply of functional cardiomyocytes for drug development and disease modeling.
- Paves the way for clinically safe, non-viral cardiac cell generation for regenerative medicine.
Background:
The production of cardiomyocytes from human induced pluripotent stem cells (hiPSC) holds great promise for patient-specific cardiotoxicity drug testing, disease modeling, and cardiac regeneration. However, existing protocols for the differentiation of hiPSC to the cardiac lineage are inefficient and highly variable. We describe a highly efficient system for differentiation of human embryonic stem cells (hESC) and hiPSC to the cardiac lineage. This system eliminated the variability in cardiac differentiation capacity of a variety of human pluripotent stem cells (hPSC), including hiPSC generated from CD34(+) cord blood using non-viral, non-integrating methods.
Methodology/Principal Findings:
We systematically and rigorously optimized >45 experimental variables to develop a universal cardiac differentiation system that produced contracting human embryoid bodies (hEB) with an improved efficiency of 94.7±2.4% in an accelerated nine days from four hESC and seven hiPSC lines tested, including hiPSC derived from neonatal CD34(+) cord blood and adult fibroblasts using non-integrating episomal plasmids. This cost-effective differentiation method employed forced aggregation hEB formation in a chemically defined medium, along with staged exposure to physiological (5%) oxygen, and optimized concentrations of mesodermal morphogens BMP4 and FGF2, polyvinyl alcohol, serum, and insulin. The contracting hEB derived using these methods were composed of high percentages (64-89%) of cardiac troponin I(+) cells that displayed ultrastructural properties of functional cardiomyocytes and uniform electrophysiological profiles responsive to cardioactive drugs.
Conclusion/Significance:
This efficient and cost-effective universal system for cardiac differentiation of hiPSC allows a potentially unlimited production of functional cardiomyocytes suitable for application to hPSC-based drug development, cardiac disease modeling, and the future generation of clinically-safe nonviral human cardiac cells for regenerative medicine.
